Back to top
more

Aileron Therapeutics (ALRN)

(Delayed Data from NSDQ)

$3.20 USD

3.20
24,872

-0.01 (-0.31%)

Updated May 31, 2024 04:00 PM ET

After-Market: $3.21 +0.01 (0.31%) 7:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ALRN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Aileron Therapeutics, Inc. [ALRN]

Reports for Purchase

Showing records 21 - 40 ( 42 total )

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

11/16/2020

Company Report

Pages: 8

3Q20 Results; ALRN-6924 Phase 1b Study Could Start in 2Q21, Two Quarters Earlier Than Previously Thought

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

10/26/2020

Company Report

Pages: 8

ALRN-6924 Phase 1b Data at the 2020 EORTC-NCI-AACR Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

09/17/2020

Company Report

Pages: 7

ALRN-6924 Phase 1b Data in SCLC Expected at EORTC-NCIAACR 2020 Conference; NSCLC Study Expected to Start 2H21

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

08/06/2020

Company Report

Pages: 7

2Q20 Results; ALRN-6924 Remains on Track, More Data Expected in 4Q20

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

08/03/2020

Daily Note

Pages: 3

Full Enrollment Achieved in ALRN-6924 Phase 1b Dose Optimization Expansion Cohort

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

06/29/2020

Daily Note

Pages: 3

Enrollment Initiated in Schedule Optimization Part of the Phase 1b/2 Trial Evaluating ALRN-6924 in SCLC; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

06/05/2020

Company Report

Pages: 7

Lowering PT to $2 Due to Dilution From Stock Offering

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

06/02/2020

Company Report

Pages: 8

ALRN-6924 Interim Results Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

05/27/2020

Daily Note

Pages: 3

Expansion Cohort Initiated in Phase 1b/2 Trial Evaluating ALRN-6924 in SCLC

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

05/11/2020

Company Report

Pages: 8

1Q20 Results; More ALRN-6924 Data Later This Quarter and in 4Q20; Reiterate $3 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

04/22/2020

Daily Note

Pages: 3

More Phase 1b/2 Interim Results for ALRN-6924 in SCLC Expected Mid-2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

03/31/2020

Company Report

Pages: 8

4Q19 Results; Discontinuing ALRN-6924 in Combination With Ibrance

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

11/08/2019

Company Report

Pages: 8

3Q19 Results; ALRN-6924 Topline Data From Two Studies Expected in 2Q20

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

10/16/2019

Daily Note

Pages: 3

First Clinical Trial of ALRN-6924 as a Myelopreservation Agent Initiated

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

09/30/2019

Company Report

Pages: 8

ALRN-6924 Interim Data Presented at ESMO; Topline Data Expected 2Q20

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

09/11/2019

Company Report

Pages: 7

HCW Global Investment Conference; Highlights From Aileron Presentation

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

08/07/2019

Company Report

Pages: 8

2Q19 Results; ALRN-6924 Data Expected at ESMO

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

06/27/2019

Daily Note

Pages: 3

FDA Accepts IND for ALRN-6924 as a Myelopreservation Agent

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

05/09/2019

Company Report

Pages: 9

1Q19 Results: ALRN-6924 Enrolling Ahead of Schedule; Raising PT by $1 to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

05/06/2019

Company Report

Pages: 5

Model Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party